An Open-Label, Dose-Escalation Study of AZD2461

Study identifier:D3660C00001

ClinicalTrials.gov identifier:NCT01247168

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients with Refractory Solid Tumors

Medical condition

Refractory solid tumors

Phase

Phase 1

Healthy volunteers

Study drug

AZD2461

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 30 Nov 2010

Primary Completion Date: 31 May 2011

Study Completion Date: 31 May 2011

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2025 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Nashville, TN, United States

Arms	Assigned Interventions
Experimental: 1	Drug: AZD2461 oral capsules, continuous dosing and intermittent dosing

Documents available

CSR-D3660C00001.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Cancer Study Locator Service

877-400-4656

astrazeneca@emergingmed.com

Investigators

Principal Investigator

Andrew Hughes

AstraZeneca